Veradermics, Incorporated

Novo Nordisk is diversifying beyond its GLP-1 obesity and diabetes franchise, aiming to launch more than five potential blockbuster drugs by 2030 and generate over $23 billion in pipeline-related sales by 2035. The company, whose Ozempic and Wegovy have driven recent growth, has begun exploring the hair-loss market, which its Chief Scientific Officer says can leverage Novo's scientific knowledge, and plans to advance multiple Phase 3 programs across obesity, diabetes and other therapeutic areas. Chief Executive Mike Doustdar acknowledged the loss of confidence, saying it takes time and hard work to build back, after the company's post-Wegovy strategy presentation sent hair-loss drug developers Veradermics and Absci higher. Novo has lost ground to rival Lilly in the injectable GLP-1 market and faces key semaglutide patent expirations in major markets in the early 2030s, prompting Morgan Stanley to downgrade the stock to Sell on medium-term growth concerns. Novo trades at around 10.2x forward GAAP earnings, below its five-year average of 30.0x and the sector median of 23.3x, while its forward price-to-sales ratio of 3.8x is below its five-year average of 9.6x and broadly in line with the sector median of 3.7x.

Baron Health Care Fund highlighted Veradermics, Incorporated in its second-quarter 2026 investor letter, noting the clinical-stage biopharmaceutical company's VDPHL01 candidate demonstrated robust hair growth in a Phase 3 trial for male pattern hair loss. Up to 63% of male patients reported improved hair coverage compared to just 13% on placebo. The fund awaits data from a second Phase 3 study in males and the first Phase 2 data in females, both expected in the second half of 2026. If approved by the FDA, VDPHL01 would be the first FDA-approved oral treatment in several decades for a condition affecting 80 million Americans. Veradermics shares closed at $101.89 on August 3, 2026, with a market capitalization of $4.26 billion.

Connecticut Innovations generated a record $66.5 million in cash proceeds from portfolio exits in fiscal year 2026, part of a combined $76.1 million from all investment activities. The state's strategic venture capital arm invested $59.3 million in 75 early-stage companies and venture funds, leveraging an additional $1.2 billion in outside capital. Key exits included Halda Therapeutics acquired by Johnson & Johnson for $3.05 billion, Quantum Circuits Inc. acquired by D-Wave Quantum for $550 million, and Veradermics raising $256.3 million in a NYSE IPO. CEO Matt McCooe highlighted Halda Therapeutics as the largest private biotech M&A transaction and Veradermics as the best-performing biotech IPO at the time. CI also launched its AI/Q Fund targeting commercial AI and quantum ventures, with director Gwen Cheni noting the Quantum Circuits acquisition as a milestone for the state's quantum ecosystem.

Biotechnology and pharmaceutical IPOs have generated a weighted average return of 55% in the U.S. market this year, sharply outperforming the broader market's 4.4% weighted average loss, according to Bloomberg data through July 17. The strong performance is drawing more drug developers to go public, with at least six filing this month, led by Scribe Therapeutics, and the number of completed biotech IPOs in 2026 already surpassing last year's total while proceeds exceed $5 billion, roughly three times the prior year's amount. Parabilis Medicines raised $770.6 million in the largest biotech IPO on record, and Veradermics has gained more than 500% since its February debut, making it the best-performing U.S. IPO across all sectors. The sector's recovery is supported by a 13% gain in the Nasdaq Biotechnology Index, a stable regulatory environment, and renewed acquisition activity, including three deals valued at $10 billion or more announced in the past month involving AbbVie, GSK, and Vertex Pharmaceuticals. Investment bankers note that major fund groups are reallocating capital toward healthcare, though higher interest rates could pose a headwind.

The healthcare sector saw multiple U.S. FDA approvals, including Novartis’ Fabhalta for IgA nephropathy and Merck’s LIPFENDRA for hypercholesterolemia, alongside Eli Lilly’s $2.8 billion acquisition of AtaiBeckley. Novartis received traditional FDA approval for Fabhalta as the first complement inhibitor for adults with primary IgAN at risk of progression, while Merck won approval for LIPFENDRA, the first once-daily oral PCSK9 inhibitor, which cut LDL-C by up to 59% in the Phase 3 CORALreef trial. Eli Lilly agreed to acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash plus up to $2.50 per share in a contingent value right, with the upfront cash consideration of approximately $2.8 billion and the CVR representing an additional potential value of approximately $1.0 billion. Other notable developments included Veradermics reporting positive Phase 2 results for its oral minoxidil formulation VDPHL01 in women with pattern hair loss, where a 4.5 mg once-daily dose led to an average increase of 22.7 hairs per square centimetre, and Insmed announcing encouraging 12-month data for its treprostinil palmitil inhalation powder in pulmonary arterial hypertension.

Apollomics shares surged over 22% on Wednesday after the company regained compliance with Nasdaq's Market Value of Listed Securities requirement. The clinical-stage firm, whose lead program is the c-Met inhibitor Vebreltinib for non-small cell lung cancer, was notified on July 8 that the matter had been closed. Other notable movers included Iovance Biotherapeutics, up more than 20% ahead of its second-quarter report, where Amtagvi revenue is expected between $79 million and $81 million, about 23% higher than in the fourth quarter of 2025. AVITA Medical rose over 17% before its own second-quarter update, while Annexon gained more than 17% in anticipation of a presentation at the American Society of Retina Specialists meeting and upcoming pivotal data from its Phase 3 ARCHER II trial in geographic atrophy. Veradermics climbed over 12% after reporting positive Phase 2 results for its oral minoxidil formulation VDPHL01 in female pattern hair loss, with 88.9% of once-daily patients reporting improved or much improved outcomes by month six.